Sentinel lymph node biopsy for cutaneous squamous cell carcinoma of the head and neck
The purpose of this study is to research if a type of biopsy known as sentinel lymph node biopsy (SLNB) can help in determining the rate of tumor deposits that are hard to detect and identify in node-negative cutaneous squamous cell carcinoma of the head or neck.
During a baseline visit, researchers will complete a biopsy to confirm diagnosis of invasice cutaneous squamous cell carcinoma, as well as Spectral CT with contrast, MRI with contrast, PET-CT and/or PET-MRI.
During intervention, researchers will complete a pre-operative lymphoscintigraphy, surgery (either Moh's micrographic or standard excision), and gene profiling.
Participants will complete a follow-up visit approximately 1 week and 4 weeks after surgery, as well as every 3 months thereafter for 1 year. Researchers will review participant medical records related to the outcome of their SLNB for up to 2 years following surgery.
You may be eligible for this study if you meet the following criteria:
- Conditions: 2008504996, cutaneous squamous cell carcinoma
Age: Between 18 Years - 100 Years
Gender: Male or Female
Individuals at least 18 years of age, with primary or recurrent invasive cutaneous squamous cell carcinoma of the head or neck, clinically staged T2-T4 based on AJCC staging, able to undergo CT scan with contrast or MRI with contrast, and surgical resection within 4 weeks of imaging.
Individuals with clinical evidence of satellite lesions, in-transit, regional nodal or distant metastases will not be eligible.
Women who are pregnant will not be eligible.